{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"This field captured the maximum dose of dasatinib administered.","groups":[{"description":"35 mg/m\\^2/dose BID PO Dasatinib x 17 days\n\nIfosfamide, Carboplatin, Etoposide\n\ntherapeutic conventional surgery\n\nradiation therapy","id":"OG000","title":"Period 1: 35 mg/m^2/Dose BID PO Dasatinib x 17 Days"}],"paramType":"NUMBER","populationDescription":"Level -1: 25 mg/m\\^2/dose BID PO Dasatinib x 17 days. Period 1: 35 mg/m\\^2/dose BID PO Dasatinib x 17 days. Period 2: 50 mg/m\\^2/dose BID PO Dasatinib x 17 days. Period 3: 65 mg/m\\^2/dose BID PO Dasatinib x 17 days. Period 4: 85 mg/m\\^2/dose BID PO Dasatinib x 17 days. Period 5 (Dasatinib alone phase only): 110 mg/m\\^2/dose BID PO. Sponsor withdrew support before a second level could be attempted.","reportingStatus":"POSTED","timeFrame":"28 days after start of course 1","title":"Maximum Administered Dose of Dasatinib (Phase I)","type":"PRIMARY","unitOfMeasure":"mg/m2 dose BID"}